Glutamate is the predominant excitatory neurotransmitter in the human brain and it has been
shown that prolonged activation of the glutamatergic system leads to nerve damage and …

Growing evidence suggests that inflammatory responses, in both the brain and peripheral
tissues, contribute to disease pathology in Huntington’s disease (HD), an inherited, …

Background Inflammatory responses play key roles in the development and progression of
many pathological conditions, including neurodegenerative diseases. Accurate quantification …

Measuring Huntingtin (HTT) protein in peripheral cells represents an essential step in
biomarker discovery for Huntington’s Disease (HD), however to date, investigations into the …

Background The recently proposed Huntington's Disease Integrated Staging System (HD-ISS)
categorises individuals with the Huntintin genetic mutation into disease progression …

Objective To investigate whether plasma NfL levels correlate with clinical symptom severity
in premanifest (PM) and manifest HD (HD) individuals, and whether a NfL cut-point could …

Objective The narrow therapeutic window of lithium medications necessitates frequent serum
monitoring, which can be expensive and inconvenient for the patient. Compared to blood, …

Mild traumatic brain injury (mTBI)-associated blood proteomics have become an emerging
focus in the past decade, with the US Food and Drug Administration recently approving the …

Catechol-O-methyltransferase (COMT) is an enzyme that catalyses the O-methylation, and
thereby the inactivation, of catechol-containing molecules. In humans, it has been suggested …

Introduction The inclusion of premanifest Huntington's Disease (Pre-HD) subjects in clinical
trials necessitates selecting those who are near transition to manifest Huntington's disease (…